How a generation of U.S. scientists were undermined by NIH cuts

And prescription drug spending explodes at major health insurers, driven by GLP-1s

December 8, 2025 Check out STAT+

Sponsored By

Lexey Swall for STAT NIH shut out hundreds of young scientists from funding to start their own labs Early-career scientists adjust to NIH ending a program that helped postdocs start their own labs. Part 5 of "American Science, Shattered." By Anil Oza and J. Emory Parker STAT+ | Kymera drug positioned to rival Sanofi and Regeneron's Dupixent succeeds in early-stage eczema trial Now, Kymera will aim to show its experimental drug helps patients with eczema and asthma in larger clinical trials. By Jonathan Wosen STAT+ | Results in Terns leukemia drug study suggest it could be a successor to Novartis blockbuster Terns leukemia drug results presented at ASH suggest it could be a successor to Novartis' blockbuster Scemblix. By Adam Feuerstein Adobe STAT+ | Driven by GLP-1s, prescription drug spending explodes at major health insurers Some insurers spent more on drugs in nine months this year than they did in all of 2024. Weight loss drugs a major factor, a STAT analysis finds. By Bob Herman STAT+ | Is AI ready to interpret chest X-rays without human supervision? In radiology, an early adopter of health AI, a debate is brewing: Should generative AI models interpret medical images on their own?  By Katie Palmer STAT+ | New data from Gilead, Arcellx multiple myeloma CAR-T suggest benefit over rival treatment At the American Society of Hematology annual meeting, Gilead and Arcellx reported promising data for their multiple myeloma CAR-T therapy anito-cel. By Adam Feuerstein Adobe Opinion: We wrote the HHS review on treatment for minors with gender dysphoria. We hope our critics actually read our report Authors of a new HHS report on medical treatment for kids and teens with gender dysphoria argue that their work aligns with growing international consensus. By Evgenia Abbruzzese, Alex Byrne, Farr Curlin, Moti Gorin, Kristopher Kaliebe, Michael K. Laidlaw, Kathleen McDeavitt, Leor Sapir, and Yuan Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser